Search Grant Opportunities

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

ID: PAR-28-042 • Prior Funding IDs: PAR-26-091 • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Analyze Opportunity
Generate a Draft
Loading

Description

Updated:
Amendment Snapshot: The opportunity changed from Forecasted to Posted. The application deadline is now November 16, 2029; the prior value was an estimated response date of February 8, 2027, not a posted deadline. Eligibility information now expressly states that foreign organizations and non-U.S. components of U.S. organizations may not apply, while foreign components of U.S. organizations are allowed; applicants are directed to Section III for additional eligibility details. The agency contact changed from Cancer Diagnosis Program (240-276-5748) to NIH (301-402-2541), with email contact NCI CDPNOFO@mail.nih.gov. The archive date moved from November 2, 2026 to January 15, 2030.
Government Description:

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.

Overview

Category of Funding
Health
Funding Instruments
Cooperative Agreement
Grant Program (CFDA)
93.CA1
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 11/3/26 the National Institutes of Health posted grant opportunity PAR-28-042 for Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed).

Timing

Posted Date
Closing Date
Due in 1095 Days
Last Updated
Version
1
Archive Date

Eligibility

Eligible Applicants
For profit organizations other than small businesses
Private institutions of higher education
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Special district governments
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal governments (Federally recognized)
Small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Additional Info
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Contacts

Contact
National Institutes of Health
Contact Email
Contact Phone
(301) 402-2541

Documents

Posted documents for PAR-28-042

Opportunity Assistant


Analyze Opportunity

Generate a Draft

Potential Applicants and Partners

Awardees that have recently won grants similar to PAR-28-042

Incumbent or Similar Grants

Grants similar to PAR-28-042

Similar Active Opportunities

Open grant opportunities similar to PAR-28-042

Experts for Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Recommended subject matter experts available for hire